356 related articles for article (PubMed ID: 32546241)
1. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma.
Zhou X; Chen N; Xu H; Zhou X; Wang J; Fang X; Zhang Y; Li Y; Yang J; Wang X
J Hematol Oncol; 2020 Jun; 13(1):77. PubMed ID: 32546241
[TBL] [Abstract][Full Text] [Related]
2. Klotho, an anti-aging gene, acts as a tumor suppressor and inhibitor of IGF-1R signaling in diffuse large B cell lymphoma.
Zhou X; Fang X; Jiang Y; Geng L; Li X; Li Y; Lu K; Li P; Lv X; Wang X
J Hematol Oncol; 2017 Feb; 10(1):37. PubMed ID: 28153033
[TBL] [Abstract][Full Text] [Related]
3. Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells.
Strömberg T; Feng X; Delforoush M; Berglund M; Lin Y; Axelson M; Larsson O; Georgii-Hemming P; Lennartsson J; Enblad G
Med Oncol; 2015 Jul; 32(7):188. PubMed ID: 26021470
[TBL] [Abstract][Full Text] [Related]
4. Control of apoptosis in human multiple myeloma by insulin-like growth factor I (IGF-I).
Jernberg-Wiklund H; Nilsson K
Adv Cancer Res; 2007; 97():139-65. PubMed ID: 17419944
[TBL] [Abstract][Full Text] [Related]
5. YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor.
Zhi X; Zhao D; Zhou Z; Liu R; Chen C
Am J Pathol; 2012 Jun; 180(6):2452-61. PubMed ID: 22632819
[TBL] [Abstract][Full Text] [Related]
6. Verteporfin inhibits YAP-induced bladder cancer cell growth and invasion via Hippo signaling pathway.
Dong L; Lin F; Wu W; Liu Y; Huang W
Int J Med Sci; 2018; 15(6):645-652. PubMed ID: 29725256
[TBL] [Abstract][Full Text] [Related]
7. ZNF213 negatively controls triple negative breast cancer progression via Hippo/YAP signaling.
Liu Y; Su P; Zhao W; Li X; Yang X; Fan J; Yang H; Yan C; Mao L; Ding Y; Zhu J; Niu Z; Zhuang T
Cancer Sci; 2021 Jul; 112(7):2714-2727. PubMed ID: 33939216
[TBL] [Abstract][Full Text] [Related]
8. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
[TBL] [Abstract][Full Text] [Related]
9. Angiomotin promotes breast cancer cell proliferation and invasion.
Lv M; Lv M; Chen L; Qin T; Zhang X; Liu P; Yang J
Oncol Rep; 2015 Apr; 33(4):1938-46. PubMed ID: 25647626
[TBL] [Abstract][Full Text] [Related]
10. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
[TBL] [Abstract][Full Text] [Related]
11. Expression and effects of inhibition of type I insulin-like growth factor receptor tyrosine kinase in mantle cell lymphoma.
Vishwamitra D; Shi P; Wilson D; Manshouri R; Vega F; Schlette EJ; Amin HM
Haematologica; 2011 Jun; 96(6):871-80. PubMed ID: 21330319
[TBL] [Abstract][Full Text] [Related]
12. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.
Yang Y; Kelly P; Shaffer AL; Schmitz R; Yoo HM; Liu X; Huang DW; Webster D; Young RM; Nakagawa M; Ceribelli M; Wright GW; Yang Y; Zhao H; Yu X; Xu W; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza L; Staudt LM
Cancer Cell; 2016 Apr; 29(4):494-507. PubMed ID: 27070702
[TBL] [Abstract][Full Text] [Related]
13. Activated Hippo/Yes-Associated Protein Pathway Promotes Cell Proliferation and Anti-apoptosis in Endometrial Stromal Cells of Endometriosis.
Song Y; Fu J; Zhou M; Xiao L; Feng X; Chen H; Huang W
J Clin Endocrinol Metab; 2016 Apr; 101(4):1552-61. PubMed ID: 26977530
[TBL] [Abstract][Full Text] [Related]
14. Estrogen regulates Hippo signaling via GPER in breast cancer.
Zhou X; Wang S; Wang Z; Feng X; Liu P; Lv XB; Li F; Yu FX; Sun Y; Yuan H; Zhu H; Xiong Y; Lei QY; Guan KL
J Clin Invest; 2015 May; 125(5):2123-35. PubMed ID: 25893606
[TBL] [Abstract][Full Text] [Related]
15. RARγ Downregulation Contributes to Colorectal Tumorigenesis and Metastasis by Derepressing the Hippo-Yap Pathway.
Guo PD; Lu XX; Gan WJ; Li XM; He XS; Zhang S; Ji QH; Zhou F; Cao Y; Wang JR; Li JM; Wu H
Cancer Res; 2016 Jul; 76(13):3813-25. PubMed ID: 27325643
[TBL] [Abstract][Full Text] [Related]
16. YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway.
Wang C; Gu C; Jeong KJ; Zhang D; Guo W; Lu Y; Ju Z; Panupinthu N; Yang JY; Gagea MM; Ng PK; Zhang F; Mills GB
Cancer Res; 2017 Apr; 77(7):1637-1648. PubMed ID: 28202507
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of YAP suppresses CML cell proliferation and enhances efficacy of imatinib in vitro and in vivo.
Li H; Huang Z; Gao M; Huang N; Luo Z; Shen H; Wang X; Wang T; Hu J; Feng W
J Exp Clin Cancer Res; 2016 Sep; 35(1):134. PubMed ID: 27599610
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
19. Elucidation of WW domain ligand binding specificities in the Hippo pathway reveals STXBP4 as YAP inhibitor.
Vargas RE; Duong VT; Han H; Ta AP; Chen Y; Zhao S; Yang B; Seo G; Chuc K; Oh S; El Ali A; Razorenova OV; Chen J; Luo R; Li X; Wang W
EMBO J; 2020 Jan; 39(1):e102406. PubMed ID: 31782549
[TBL] [Abstract][Full Text] [Related]
20. YAP activation is an early event and a potential therapeutic target in liver cancer development.
Perra A; Kowalik MA; Ghiso E; Ledda-Columbano GM; Di Tommaso L; Angioni MM; Raschioni C; Testore E; Roncalli M; Giordano S; Columbano A
J Hepatol; 2014 Nov; 61(5):1088-96. PubMed ID: 25010260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
